Flagship Pioneering Fund VII, L.P. 3
3 · Foghorn Therapeutics Inc. · Filed May 24, 2024
Insider Transaction Report
Form 3
Flagship Pioneering Fund VII General Partner LLC
Director10% Owner
Holdings
- (indirect: By Flagship Pioneering Fund VII, L.P.)
Pre-Funded Warrants to purchase Common Stock
Exercise: $0.00→ Common Stock (1,814,915 underlying)
Footnotes (2)
- [F1]On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants (the "Pre-Funded Warrants") to purchase 1,814,915 shares of Common Stock at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
- [F2]Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.